<p>LB Pharmaceuticals Inc（纳斯达克：LBRX - 获取免费报告）在周二的交易中达到了新的 52 周高点。该公司的股价最高达到 32.49 美元，最后交易价格为 31.67 美元，成交量为 208549 股。该股票此前收盘价为 30.52 美元。</p>
<p>获取 <strong>LB Pharmaceuticals</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>多家研究分析师最近对该股票发布了报告。Stifel Nicolaus 将 LB Pharmaceuticals 的股票目标价从 35.00 美元上调至 40.00 美元，并在 3 月 27 日的研究报告中给予该股票 “买入” 评级。Craig Hallum 在 4 月 10 日的研究报告中开始覆盖 LB Pharmaceuticals 的股票。他们给予该股票 “买入” 评级和 36.00 美元的目标价。Roth Mkm 在 1 月 9 日的研究报告中开始覆盖 LB Pharmaceuticals 的股票。他们给予该股票 “买入” 评级和 31.00 美元的目标价。最后，Weiss Ratings 在 12 月 29 日的研究报告中重申了对 LB Pharmaceuticals 的 “卖出（e）” 评级。一位研究分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，LB Pharmaceuticals 的共识评级为 “适度买入”，平均目标价为 35.25 美元。</p>
<p><strong>获取我们对 LBRX 的最新分析</strong></p>
<h2>LB Pharmaceuticals 股价上涨 3.8%</h2>
<p>该股票的 50 日移动平均价格为 24.94 美元，200 日移动平均价格为 20.95 美元。该公司的市值为 9.0798 亿美元，市盈率为-29.88。</p>
<p>LB Pharmaceuticals（纳斯达克：LBRX - 获取免费报告）最近在 3 月 26 日发布了季度财报。该公司报告每股收益（EPS）为-0.45 美元，符合分析师的共识预期（-0.45 美元）。卖方分析师预计 LB Pharmaceuticals Inc 在当前财年将发布-3.85 美元的每股收益。</p>
<h2>LB Pharmaceuticals 的机构交易</h2>
<p>多家大型投资者最近调整了对 LBRX 的持股。加利福尼亚州教师退休系统在第四季度新购入了 LB Pharmaceuticals 的股份，价值约 26,000 美元。美国银行在第三季度新购入了 LB Pharmaceuticals 的股份，价值约 27,000 美元。拉塞尔投资集团在第四季度新购入了 LB Pharmaceuticals 的股份，价值约 34,000 美元。Strs Ohio 在第四季度新购入了 LB Pharmaceuticals 的股份，价值约 76,000 美元。最后，Persistent Asset Partners Ltd 在第四季度新购入了 LB Pharmaceuticals 的股份，价值约 91,000 美元。</p>
<h2>LB Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>我们是一家临床阶段的生物制药公司，开发用于治疗精神分裂症、双相抑郁症和其他神经精神疾病的新疗法。我们正在建立一个利用我们主要产品候选药物 LB-102 广泛治疗潜力的产品线，我们相信该药物有潜力成为美国首个获批用于神经精神疾病的苯酰胺类抗精神病药物。LB-102 是一种新化合物，是阿米舒利普的甲基化衍生物，阿米舒利普是一种在超过 50 个国家获批的第二代抗精神病药物，但不包括美国，因为美国的开发和监管要求。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 LB Pharmaceuticals</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 LB Pharmaceuticals 吗？</h2>
<p>在你考虑 LB Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 LB Pharmaceuticals 并不在名单上。</p>
<p>虽然 LB Pharmaceuticals 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LBRX

<p>LB Pharmaceuticals（纳斯达克代码：LBRX）在交易中达到了新的 52 周高点 32.49 美元，收盘价为 31.67 美元。分析师们提高了目标价格，Stifel Nicolaus 将其目标价从 35.00 美元上调至 40.00 美元，并维持 “买入” 评级。该股票的共识评级为 “适度买入”，平均目标价格为 35.25 美元。公司报告每股收益为（0.45 美元），符合预期。机构投资者最近增加了对 LB Pharmaceuticals 的持股，该公司专注于开发神经精神疾病的治疗方案</p>

<p>LB Pharmaceuticals Inc (NASDAQ:LBRX - Get Free Report) reached a new 52-week high during trading on Tuesday . The company traded as high as $32.49 and last traded at $31.67, with a volume of 208549 shares trading hands. The stock had previously closed at $30.52.</p>
<div class="lb-trans"><p>LB Pharmaceuticals Inc（纳斯达克：LBRX - 获取免费报告）在周二的交易中达到了新的 52 周高点。该公司的股价最高达到 32.49 美元，最后交易价格为 31.67 美元，成交量为 208549 股。该股票此前收盘价为 30.52 美元。</p>
</div><p>Get <strong>LB Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>LB Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of research analysts have recently issued reports on the stock. Stifel Nicolaus raised their price target on shares of LB Pharmaceuticals from $35.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 27th. Craig Hallum assumed coverage on shares of LB Pharmaceuticals in a research report on Friday, April 10th. They issued a &#34;buy&#34; rating and a $36.00 price target on the stock. Roth Mkm assumed coverage on shares of LB Pharmaceuticals in a research report on Friday, January 9th. They issued a &#34;buy&#34; rating and a $31.00 price target on the stock. Finally, Weiss Ratings restated a &#34;sell (e)&#34; rating on shares of LB Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, LB Pharmaceuticals has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $35.25.</p>
<div class="lb-trans"><p>多家研究分析师最近对该股票发布了报告。Stifel Nicolaus 将 LB Pharmaceuticals 的股票目标价从 35.00 美元上调至 40.00 美元，并在 3 月 27 日的研究报告中给予该股票 “买入” 评级。Craig Hallum 在 4 月 10 日的研究报告中开始覆盖 LB Pharmaceuticals 的股票。他们给予该股票 “买入” 评级和 36.00 美元的目标价。Roth Mkm 在 1 月 9 日的研究报告中开始覆盖 LB Pharmaceuticals 的股票。他们给予该股票 “买入” 评级和 31.00 美元的目标价。最后，Weiss Ratings 在 12 月 29 日的研究报告中重申了对 LB Pharmaceuticals 的 “卖出（e）” 评级。一位研究分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，LB Pharmaceuticals 的共识评级为 “适度买入”，平均目标价为 35.25 美元。</p>
</div><p><strong>Get Our Latest Analysis on LBRX</strong></p>
<div class="lb-trans"><p><strong>获取我们对 LBRX 的最新分析</strong></p>
</div><h2>LB Pharmaceuticals Trading Up 3.8%</h2>
<div class="lb-trans"><h2>LB Pharmaceuticals 股价上涨 3.8%</h2>
</div><p>The stock's 50-day moving average price is $24.94 and its 200-day moving average price is $20.95. The company has a market capitalization of $907.98 million and a P/E ratio of -29.88.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均价格为 24.94 美元，200 日移动平均价格为 20.95 美元。该公司的市值为 9.0798 亿美元，市盈率为-29.88。</p>
</div><p>LB Pharmaceuticals (NASDAQ:LBRX - Get Free Report) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.45). Sell-side analysts expect that LB Pharmaceuticals Inc will post -3.85 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>LB Pharmaceuticals（纳斯达克：LBRX - 获取免费报告）最近在 3 月 26 日发布了季度财报。该公司报告每股收益（EPS）为-0.45 美元，符合分析师的共识预期（-0.45 美元）。卖方分析师预计 LB Pharmaceuticals Inc 在当前财年将发布-3.85 美元的每股收益。</p>
</div><h2>Institutional Trading of LB Pharmaceuticals</h2>
<div class="lb-trans"><h2>LB Pharmaceuticals 的机构交易</h2>
</div><p>A number of large investors have recently modified their holdings of LBRX. California State Teachers Retirement System acquired a new stake in shares of LB Pharmaceuticals in the 4th quarter worth about $26,000. Bank of America Corp DE acquired a new stake in shares of LB Pharmaceuticals in the 3rd quarter worth about $27,000. Russell Investments Group Ltd. acquired a new stake in shares of LB Pharmaceuticals in the 4th quarter worth about $34,000. Strs Ohio acquired a new stake in shares of LB Pharmaceuticals in the 4th quarter worth about $76,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of LB Pharmaceuticals in the 4th quarter worth about $91,000.</p>
<div class="lb-trans"><p>多家大型投资者最近调整了对 LBRX 的持股。加利福尼亚州教师退休系统在第四季度新购入了 LB Pharmaceuticals 的股份，价值约 26,000 美元。美国银行在第三季度新购入了 LB Pharmaceuticals 的股份，价值约 27,000 美元。拉塞尔投资集团在第四季度新购入了 LB Pharmaceuticals 的股份，价值约 34,000 美元。Strs Ohio 在第四季度新购入了 LB Pharmaceuticals 的股份，价值约 76,000 美元。最后，Persistent Asset Partners Ltd 在第四季度新购入了 LB Pharmaceuticals 的股份，价值约 91,000 美元。</p>
</div><h2>LB Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>LB Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.</p>
<div class="lb-trans"><p>我们是一家临床阶段的生物制药公司，开发用于治疗精神分裂症、双相抑郁症和其他神经精神疾病的新疗法。我们正在建立一个利用我们主要产品候选药物 LB-102 广泛治疗潜力的产品线，我们相信该药物有潜力成为美国首个获批用于神经精神疾病的苯酰胺类抗精神病药物。LB-102 是一种新化合物，是阿米舒利普的甲基化衍生物，阿米舒利普是一种在超过 50 个国家获批的第二代抗精神病药物，但不包括美国，因为美国的开发和监管要求。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than LB Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 LB Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LB Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 LB Pharmaceuticals 吗？</h2>
</div><p>Before you consider LB Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 LB Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LB Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 LB Pharmaceuticals 并不在名单上。</p>
</div><p>While LB Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 LB Pharmaceuticals 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High  - Time to Buy?

Market Beat

LB Pharmaceuticals

Stifel Financial

美国银行

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

LB Pharmaceuticals（NASDAQ:LBRX）创下 52 周新高 - 现在是买入的好时机吗？